Atai Beckley NV (ATAI) Stock Price, Financials & Summary

Price chart

Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11

Key dataSep 11, 2026

Open$7.35

From 52W high−1.21%

Volume0.00

Market cap$2.73B

P/E (TTM)—

P/S (TTM)609.4x

Div yield91.84%

Key dataSep 11, 2026

Open

$7.35

From 52W high

−1.21%

Volume

0.00

Market cap

$2.73B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.7x

P/E (TTM)

—

RSI (14)

61.8

MomentumView details →

1D Return

+0.00%

YTD Return

+79.71%

SummaryUpdated Jun 1, 2026

Atai Life Sciences N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Berlin, Germany. The company went public in June 2021 and focuses on developing innovative therapeutic candidates for various mental health disorders. Atai operates through a platform approach, advancing multiple drug candidates simultaneously across different stages of clinical development, with a particular emphasis on novel treatments for conditions like treatment-resistant depression, anxiety disorders, and substance use disorders.

Ask drillr about Atai Beckley NV →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.7x

EV/Sales

559.9x

P/S (TTM)

609.4x

P/B (TTM)

15.5x

ProfitabilityView details →

Gross Margin

86.25%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−378.87%

ROA (TTM)

−252.35%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

+93.72%

EPS YoY

—

FCF YoY

−64.38%

Revenue CAGR 3Y

+159.87%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+0.00%

YTD Return

+79.71%

1Y Return

+58.75%

RSI (14)

61.8

vs 50D SMA

+6.55%

vs 200D SMA

+55.18%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

8.58x

Quick Ratio

8.58x

Div Yield

91.84%

Div Rate

$6.75

Div Growth 1Y

+12.50%

EarningsView details →

EPS (Actual)

−$0.09

EPS Surprise

15.64%

Beats (12Q)

7/12

Next Q EPS Est

−$0.12

Avg Surprise (4Q)

−8.02%

Rev Surprise

121.07%

Financials snapshotView financials →

Revenue (TTM)

4.47M

Net Income (TTM)

−668.19M

Op. CF (TTM)

−127.78M

Next earningsNov 12, 2026 →

Latest newsMore news →

Kahn Swick & Foti, LLC announced an investigation into the adequacy of price and process in the proposed sale of AtaiBeckley Inc.34d ago

Atai Beckley Inc's stock reached a 52-week high of $7.22, reflecting a 110% gain over the last six months and a 71.89% increase over the past year.46d ago

Similar companies

国发股份600538.SH 健之佳605266.SH Shanghai Pioneer Holding Ltd01345.HK 第一医药600833.SH ST葫芦娃605199.SH 诚意药业603811.SH Find similar companies →

Latest newsMore news →

Kahn Swick & Foti, LLC announced an investigation into the adequacy of price and process in the proposed sale of AtaiBeckley Inc.34d ago Atai Beckley Inc's stock reached a 52-week high of $7.22, reflecting a 110% gain over the last six months and a 71.89% increase over the past year.46d ago